ArticleOral diseases2026
Clinicopathological and Prognostic Features of Pleomorphic Adenoma, Recurrent Pleomorphic Adenoma, and Carcinoma ex Pleomorphic Adenoma: A 20-Year Retrospective Analysis.
Article in Oral diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Pleomorphic Adenomas and Their Atypical Morphology: Pitfalls in the Diagnosis of Salivary Gland Tumors.Diagnostics (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundPleomorphic adenoma (PA) is the most common salivary gland tumor, and a subset may recur as recurrent PA (RPA) or progress to carcinoma ex pleomorphic adenoma (CXPA). However, comparative evaluations of their biological behavior and prognostic factors remain limited.
objectiveTo characterize and compare the clinical features, pathological patterns, treatment outcomes, and prognostic factors of PA, RPA, and CXPA over a 20-year period at a Brazilian tertiary referral center. MATERIALS AND
methodsA retrospective review of 234 cases (148 PA, 23 RPA, 63 CXPA) diagnosed between 2004 and 2024. Analyses included Fisher's exact test and chi-square test for group comparisons and Cox proportional hazards models for overall (OS) and disease-specific survival (DSS).
resultsPA and RPA mainly affected younger females and presented smaller tumors and shorter clinical evolution than CXPA (p < 0.01). In CXPA, perineural invasion, angiolymphatic invasion, necrosis, recurrence, symptomatology, distant metastasis, and capsular invasion pattern were associated with reduced OS and DSS (p < 0.05).
conclusionThis retrospective study demonstrates distinct clinical and pathological profiles across PA, RPA, and CXPA. In CXPA, clinical and histological factors strongly predict survival and should guide risk stratification, therapeutic decisions, and follow-up strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.